Has Yeshitila Mengesha, MD received payments from drug or device companies?

Yes. Drug and device makers reported $532 in general payments to Yeshitila Mengesha, MD across 32 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Yeshitila Mengesha, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Yeshitila Mengesha, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Yeshitila Mengesha, MD

Gastroenterology · Bismarck, NDNPI 1518298728

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 65.7% of it on its own, with 5 other manufacturers making up the rest. That places this record below the midpoint for gastroenterology clinicians in ND, where the typical reported total is $1,464.

$532in general payments, 2019–2025

Across 32 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$349
Ipsen Biopharmaceuticals, Inc$79
Sanofi$35
Takeda Pharmaceuticals U.S.A., Inc.$30
Pfizer$23
Lilly USA, LLC$16

What the payments were for

Food & beverage$532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	20	$349
Ipsen Biopharmaceuticals, Inc	5	$79
Sanofi	2	$35
Takeda Pharmaceuticals U.S.A., Inc.	2	$30
Pfizer	2	$23
Lilly USA, LLC	1	$16

How this compares

$532 in reported general payments places this provider in the 25th percentile of 26 gastroenterology providers in North Dakota.

See all gastroenterology providers in North Dakota →

Medicare billing

Part B allowed, 2024

$188,675

Medicare patients

866

Services billed

1,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	13	$94,979
LinzessLinaclotide	25	$17,810
Octreotide Acetate	12	$10,368
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	408	$7,666
Ursodiol	23	$4,347
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl	178	$3,372
Pantoprazole Sodium	146	$2,378
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C	17	$2,315
CholestyramineCholestyramine (With Sugar)	15	$1,572
Omeprazole	56	$815
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	12	$793
Lubiprostone	12	$741
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl	24	$434
Esomeprazole Magnesium	12	$374
Dicyclomine Hcl	13	$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieLinzess	$349	$17,81025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 26 gastroenterology providers in North Dakota.

Other gastroenterology in Bismarck

Syed ZaidiBismarck$6K
Mark BrewsterBismarck$4K
Douglas RentonBismarck$2K
Mustafa KathawalaBismarck$2K
Makda BsratBismarck$2K
Kevin KarlsBismarck$2K
Nicholas BattistaBismarck$1K
Tawhid GaziBismarck$572
Elida VothBismarck$31
Arezoo TaheriFargo$28K

See the full list for North Dakota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →